文献速递炎症性肠病

美沙拉秦诱导治疗后轻度至中度溃疡性结肠炎内镜改善的预测模型

Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-12-03

本研究对726例轻度至中度溃疡性结肠炎患者的美沙拉秦3期非劣效试验数据进行了事后分析,通过多变量逻辑回归建模确定第8周内镜改善(Mayo内镜子评分0-1分,盲法中心判读)的相关因素,并开发临床决策支持工具将患者分为低、中、高概率组。模型在开发数据集(AUC 0.84,95%CI 0.81-0.87)和验证中(AUC 0.83)均显示出良好的区分能力。

要点

  • 粪便钙卫蛋白较基线下降50%与第8周内镜改善相关(OR 2.64,95%CI 1.81-3.85)。
  • 直肠出血每减少1分(OR 1.79,95%CI 1.35-2.39)和医师总体评估每改善1分(OR 2.32,95%CI 1.88-2.85)与内镜改善正相关。
  • 基线Geboes评分每增加1级(OR 0.74,95%CI 0.65-0.85)和病程每延长1年(OR 0.95,95%CI 0.92-0.98)与内镜改善负相关。

核心结论

  • 开发并验证的临床决策支持工具对美沙拉秦诱导轻度至中度UC患者内镜改善具有良好区分能力,AUC在开发集为0.84(95%CI 0.81-0.87),验证集为0.83。

研究设计与样本

  • 对726例轻度至中度UC患者的美沙拉秦3期非劣效试验数据进行事后分析,采用多变量逻辑回归建模,并通过bootstrap重采样进行内部验证。

主要发现

  • 第8周内镜改善(Mayo内镜子评分0-1分,盲法中心判读)与粪便钙卫蛋白较基线下降50%(OR 2.64,95%CI 1.81-3.85)、直肠出血减少(OR 1.79每减少1分,95%CI 1.35-2.39)、医师总体评估改善(OR 2.32每改善1分,95%CI 1.88-2.85)正相关。
  • 基线Geboes评分(OR 0.74每增加1级,95%CI 0.65-0.85)和较长病程(OR 0.95每延长1年,95%CI 0.92-0.98)与内镜改善负相关。

关键数值与推荐

  • 内镜改善定义为Mayo内镜子评分0-1分(盲法中心判读)。
  • 模型在开发数据集AUC 0.84(95%CI 0.81-0.87),验证AUC 0.83。
  • 临床决策支持工具将患者分为低、中、高概率组以预测内镜改善。

临床怎么用

  • 该工具可辅助识别美沙拉秦诱导治疗后可能达到内镜改善的轻度至中度UC患者,减少不必要的早期内镜评估。

局限性

  • 本研究为事后分析,结果需在前瞻性研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Endoscopic improvement is an important treatment target for mild-to-moderate ulcerative colitis (UC). However, early endoscopic evaluation is not always feasible. We aimed to develop a clinical decision support tool to discriminate patients who have achieved endoscopic improvement from those with more severe inflammation following mesalamine induction therapy. METHODS: We performed a post-hoc analysis of data from a phase 3 non-inferiority trial of 726 adults with mild-to-moderate UC treated with mesalamine. Multivariable logistic regression modeling determined associations between candidate variables and endoscopic improvement (Mayo endoscopic subscore=0-1 according to blinded central reading) at Week 8. Internal model validation was performed using bootstrap resampling. A clinical decision support tool was developed to stratify patients into low, intermediate, and high probability groups for endoscopic improvement. RESULTS: Variables associated with endoscopic improvement at Week 8 included 50% reduction in fecal calprotectin from baseline (odds ratio [OR] 2.64, 95% CI:, 1.81, 3.85), reduction in rectal bleeding (OR 1.79 per point reduction, 95% CI: 1.35, 2.39), and improvement in physician global assessment (OR 2.32 per point improvement, 95% CI: 1.88, 2.85). The baseline Geboes score (OR 0.74 per grade, 95% CI: 0.65, 0.85) and prolonged disease duration (OR 0.95 per year, 95% CI: 0.92, 0.98) were negatively associated with endoscopic improvement. This model strongly discriminated endoscopic improvement in the development dataset (area under the curve [AUC] 0.84, 95% CI: 0.81, 0.87) and during validation (AUC 0.83). CONCLUSIONS: We developed and validated a clinical decision support tool that has good discriminative performance for induction of endoscopic improvement in patients with mild-to-moderate UC treated with mesalamine. ClinicalTrials.gov Registration: NCT01903252.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ma C, Jeyarajah J, Guizzetti L, et al. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 33279779. doi:10.1016/j.cgh.2020.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。